| COVID-19 vaccination and antirheumatic therapy J Arnold, K Winthrop, P Emery Rheumatology 60 (8), 3496-3502, 2021 | 113 | 2021 |
| Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a … MYM Yusof, J Arnold, B Saleem, C Vandevelde, S Dass, S Savic, EM Vital, ... The Lancet Rheumatology 5 (2), e88-e98, 2023 | 32 | 2023 |
| Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab J Arnold, S Dass, S Twigg, CH Jones, B Rhodes, P Hewins, ... Rheumatology 61 (12), 4905-4909, 2022 | 20 | 2022 |
| A linear epitope in the N-terminal domain of CCR5 and its interaction with antibody B Chain, J Arnold, S Akthar, M Brandt, D Davis, M Noursadeghi, T Lapp, ... PLoS One 10 (6), e0128381, 2015 | 15 | 2015 |
| A personalized rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis J Arnold, EM Vital, S Dass, A Aslam, AC Rawstron, S Savic, P Emery, ... Frontiers in Immunology 12, 803175, 2022 | 12 | 2022 |
| Predicting sustained clinical response to rituximab in moderate to severe systemic manifestations of primary Sjögren syndrome S Pepple, J Arnold, EM Vital, AC Rawstron, CT Pease, S Dass, P Emery, ... ACR Open Rheumatology 4 (8), 689-699, 2022 | 2 | 2022 |
| Op0250 breakthrough infections and predicting severe covid outcomes during rituximab therapy in autoimmune rheumatic diseases MYM Yusof, J Arnold, B Saleem, C Vandevelde, S Dass, S Savic, E Vital, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 164-164, 2022 | 1 | 2022 |
| P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome S Pepple, J Arnold, EM Vital, AC Rawstron, C Pease, S Dass, P Emery, ... Rheumatology 61 (Supplement_1), keac133. 244, 2022 | 1 | 2022 |
| P155 Identifying a population of patients for intensive first-line therapy in SLE: a clinical and biomarker model to predict the need for intensive therapy P Intapiboon, SU Hassan, J Arnold, K Mahmoud, EM Vital, MYM Yusof Lupus Science & Medicine 11 (Suppl 1), 2024 | | 2024 |
| POS1450 3-YEAR ANALYSES OF AT-RISK ANA-POSITIVE COHORT: PROGNOSTIC VALUE OF CLINICAL AND INTERFERON BIOMARKERS TOWARDS AUTOIMMUNITY MY MD Yusof, SU Hassan, Z Wigston, A Psarras, J Arnold, LM Carter, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1078-1079, 2023 | | 2023 |
| POS1516 CHARACTERISATION OF AN ANA-ARTHRITIS BASKET POPULATION FOR CLINICAL TRIALS J Arnold, LM Carter, MYMD Yusof, SU Hassan, K Dutton, Z Wigston, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1117-1117, 2023 | | 2023 |
| AB0576 DEFINING INTERFERON MEDIATED CONDITIONS (DEFINITION): IFN ASSAYS AND CLINICAL FEATURES OF ESTABLISHED ANA-ASSOCIATED AUTOIMMUNE DISEASES J Arnold, LM Carter, K Dutton, SU Hassan, Z Wigston, MYMD Yusof, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1485-1486, 2023 | | 2023 |
| POS1450 3-YEAR ANALYSES OF AT-RISK ANA-POSITIVE COHORT: PROGNOSTIC VALUE OF CLINICAL AND INTERFERON BIOMARKERS TOWARDS AUTOIMMUNITY MYMD Yusof, SU Hassan, Z Wigston, A Psarras, J Arnold, LM Carter, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 1078-1079, 2023 | | 2023 |
| OA26 Characterisation of a basket trial population for arthritis associated with ANA-positive RMDs J Arnold, LM Carter, S Hassan, K Dutton, Z Wigston, S Dass, YM Md Yusof, ... Rheumatology 62 (Supplement_2), kead104. 026, 2023 | | 2023 |
| Think Fast! Using Machine Learning Approaches to Identify Predictors of Adverse Pregnancy Outcomes in SLE. J Arnold Rheumatology Network, NA-NA, 2022 | | 2022 |
| Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases YM Yusof, J Arnold, B Saleem, C Vandevelde, S Dass, S Savic, EM Vital, ... Arthritis and Rheumatology 74 (S9), 1559-1560, 2022 | | 2022 |
| Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers LM Carter, Z Wigston, J Arnold, P Laws ARTHRITIS & RHEUMATOLOGY 74, 1923-1924, 2022 | | 2022 |
| Off Target: The Long-Term Sequelae of Inadequate Disease Control in SLE. J Arnold Rheumatology Network, NA-NA, 2022 | | 2022 |
| Class III/IV Lupus Nephritis Shows an Association with High Serum Type 1 Interferon Levels. J Arnold Rheumatology Network, NA-NA, 2022 | | 2022 |
| AB0434 EFFICACY AND SAFETY OF OBINUTUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SECONDARY NON-RESPONSE TO RITUXIMAB. J Arnold, S Dass, S Twigg, C Jones, B Rhodes, P Hewins, M Chakravorty, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 1345-1345, 2022 | | 2022 |
